Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Generalized Myasthenia Gravis
NCT07039916Phase 3Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of IMVT-1402 in myasthenia gravis (MG), sponsored by Immunovant, Inc.. Started May 2025; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07039916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039916.